News

Avexa plans to use Monogram’s assays across its virology portfolio, including the Phase III program for its lead compound, apricitabine, an anti-HIV drug. Avexa also plans to use

The study, which is being conducted at over five sites in Australia, will enroll up to 24 patients who will receive either KB002 or placebo. Endpoints for the

Financial Highlights Operating profit increased 17.9% to $13.2 million (2008: $11.2 million) EBITDA increased 13.9% to $15.6 million (2008: $13.7 million) and EBITDA margin increased to 29.7% (2008:

The decision is followed by the meeting with representatives of the FDA to discuss the previously announced failed results of company’s pivotal Phase III clinical trial of MyVax.

This patent further strengthens the company’s position in using its Gut Endocrine cell Modification System (GEMS) gene transfer technology to induce gut K-cells to produce insulin in a

The company also said that the vaccine has shown 100% efficacy in preventing precancerous lesions due to cancer-causing virus types 16 and 18 and also provided substantial protection

The trial (study 06CCL3-001) is a multi-centre, randomized, double-blind, parallel-arm study that will compare the efficacy and safety of company’s twice-daily tramadol-acetaminophen combination product. The study, which is

The sNDA submission is based on results of a multi-center, randomized, double-blind study in 699 adult patients, which demonstrated less procedural pain associated with blood draws or IV

The new facility will primarily produce infant formula milk powder and other nutritional products. The new facility will become part of Wyeth’s global nutritional manufacturing and supply network